Diaprost announces Exercise of Option under the terms of its Research and Option Agreement with a leading Pharmaceutical company
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody. An upfront payment and research funding has already been paid and an early-stage clinical trial has been initiated. In payments made prior to option exercise, Diaprost received $13M. The option fee and potential future payments, including commercial milestones, for its h11B6 antibody for prostate cancer may be up to $90 million. No